BMS petitions SCOTUS to revive $1.2bn win

BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BMS and cancer centre settle patent exploitation clash

11 April 2023 Feud concerned the ownership of six immunotherapy patents | Cancer centre claimed that it was unfairly deprived of royalties.

Big Pharma

SCOTUS rejects BMS vs Gilead patent clash

10 November 2022 Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.

Americas

Bristol Myers can’t convince circuit to overturn $1.2bn ruling

18 January 2022 The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.